Thyroid associated ophthalmopathy: Pediatric and endocrine aspects

Pediatric Endocrinology Reviews

Volumn 1, Issue SUPPL. 3, 2004, Pages 513-517

  Wiersinga, Wilmar M ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Childhood; Graves' ophthalmopathy; IGF; Octreoscan; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOSTATIN DERIVATIVE;

AUTOCRINE EFFECT; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; INCIDENCE; PARACRINE SIGNALING; PREVALENCE; SMOKING;

BIOLOGICAL MARKERS; CHILD; COLLAGEN; FIBROBLASTS; GLYCOSAMINOGLYCANS; GRAVES OPHTHALMOPATHY; HUMANS; INCIDENCE; ORBIT; PROGNOSIS;

EID: 13444259848     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota, Am J Ophthalmol 1995;120:511-517
2. Uretsky SH, Kennerdell JS, Gutai JP. Graves' ophthalmopathy in childhood and adolescence. Arch Ophthalmol 1980;98:1963-1964
3. Young LA. Dysthyroid ophthalmopathy in children. J Pediatr Ophthalmol Strabismus 1979;16:105-107
4. Gruters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes 1999;107 (suppl 5):S172-174
5. Chan W, Wong GWK, Tan DSP, et al. Ophthalmopathy in childhood Graves' disease. Br J Ophthalmol 2002;86:740-742
6. Werner SC, Coelho B, Quimby EH, Ten year result of I-131 therapy in hyperthyroidism. Bull NY Acad Med 1957;33:783-806
7. Hamilton RO, Mayberry WE, McConahey WM, Hanson KC. Ophthalmopathy of Graves' disease: a comparison between patients treated surgically and patients treated with radioiodine. Mayo Clin Proc 1967;42:812-818
8. Kriss JP, Pleshakov V, Rosenblum AL, et al. Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J Clin Endocrinal Metab 1967;27:582-593
9. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-1738
10. Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol 2003;148:491-495
11. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993;269:479-482
12. Bahn RS. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003;88:1939-1946
13. Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2004;89:930-935
14. Ludgate ME. Animal models of thyroid-associated ophthalmopathy. Thyroid 2002;12:205-208
15. Gerdins MN, Meer JWC van der, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 2000;52:267-271
16. Rotella CM, Zonefrati R, Toccafondi P, et al. Ability of monoclonal antibodies to the thyrotrophin receptor to increase collagen synthesis in human fibroblasts: An assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera. J Clin Endocrinol Metab 1986;62;357-367
17. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 2002;168:942-950
18. Hansson HA, Petruson B, Skottner A. Somatomadin C in pathogenesis of malignant exophthalmos of endocrine origin. Lancet 1986;1:218-219
19. Krassas GE. Treatment of juvenile Graves' disease and its ophthalmic complication: the 'European' way. Eur J Endocrinol 2004;150:407
20. Imai Y, Odajima R, Inoue Y, Shisiba Y. Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol 1992;126:541-552
21. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 1993;16:251-257
22. Krassas GE, Pontikides N, Kaltsas T, et al. Free and total insulin-like growth factor (IGF-1),- II and IGF binding protein -1, -2 and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003;88:132-135
23. Pasquali D, Vassallo P, Esposito D et al. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Endocrinol 2000;25:63-71
24. Pasquali D, Notaro A, Bonavolonta G, et al. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' ophthalmopathy. J Clin Endocrinol Metab 2002;87:5125-5129
25. Postema PTE, Krenning EP, Wijngaarde R, et al. [111 In -DPTA- D-Phe] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab 1994;79:1845-1851
26. Kahaly G, Dinz M, Haka K, et al. Indium -111- pentetreotide scintigraphy in Graves' ophthalmopathy. J Nucl Med 1995;36:550-554
27. Moncayo R, Baldnisera G, Decristoforo C, et al. Evolution of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111 In·octreotide. Thyroid 1997;7:21-29
28. Kahaly G, Diaz M, Just M, et al. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy. Thyroid 1995;5:107-111
29. Wiersinga WM, Gerding MN, Prummel MF, Krenning EP. Octreotide scintigraphy in thyroidal and orbital Graves' disease. Thyroid 1998;8:433-436
30. Krassas GE, Dumas A, Pontikides N, Kaltsas Th. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 1995;42:571-580
31. Colao A, Lastorin S, Ferone D, et al. Orbital scintigraphy with [111 In - DPTA- D- Phe1] octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1998;83:3790-3794
32. Gerding MN, Zan FM van der, Royen EA van, et al. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol 1999;50:373-379
33. Chang TC, Kao SCS, Hung TC. Octreotide and Graves' ophthalmopathy and pretibial myxoedema. Brit Med J 1992;304;158
34. Kung AWC, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticoid in the treatment of Graves' ophthalmopathy. Thyroid 1996;6:381-384
35. Krassas GE, Kaltsas Th, Dumas A, et al. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997;136:416-422
36. Bruns C, Lewis I, Briner U, et al. SOM 230: a new somatostatin peptidomimetic with broad SRIF receptor binding and a unique inhibitory profile. Eur J Endocrinol 2002;146:707-716